- Comparison of the performance of two targeted metagenomic virus capture probe-based methods
- using synthetic viral sequences and clinical samples
-
- 4 Kees Mourik^{1*}, Igor Sidorov¹, Ellen C. Carbo¹, David van der Meer², Arnoud Boot², Aloysius C. M. Kroes¹,
- 5 Eric C.J. Claas¹, Stefan A. Boers¹, Jutte J.C. de Vries^{1*}

6 ¹ Department of Medical Microbiology, Leiden University Center for Infectious Diseases, Leiden

University Medical Center, Leiden, the Netherlands

- 8 ² GenomeScan B.V., Leiden, the Netherlands
- *Corresponding authors
-
- Abstract

 Viral enrichment by probe hybridization has been reported to significantly increase the sensitivity of viral metagenomics.

This study compares the analytical performance of two targeted metagenomic virus capture probe-

based methods: i) SeqCap EZ HyperCap by Roche (ViroCap) and ii) Twist Comprehensive Viral Research

- Panel workflow, for diagnostic use. Sensitivity, specificity, limit of detection, and effect of human
- background DNA were analysed, using synthetic viral sequences, clinical and reference samples with
- known viral loads.

 Sensitivity and specificity were 95% and higher for both methods. Combining thresholds for viral sequence read counts and genome coverage (respectively 500 reads per million and 10% coverage) resulted in optimal prediction of true positive results. Limits of detection were approximately 50-500 22 copies/ml for both methods. Increasing proportions of spike-in cell free human background sequences did not negatively affect viral detection.

 These data show analytical performances in ranges applicable to clinical samples, for both probe hybridization metagenomic approaches. This study supports further steps towards more widespread use of viral metagenomics for pathogen detection, in clinical and surveillance settings using low biomass samples.

29 Keywords: viral metagenomics, capture probes, targeted metagenomics, viral diagnostics
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practic

30 **Introduction**

31 Viral metagenomics has been gradually applied for broad-spectrum pathogen detection of infectious 32 diseases¹⁻⁵, surveillance of emerging diseases^{3,6-8}, and pathogen discovery^{9,10}. Though metagenomic 33 approaches have been practiced for decades in the field of marine environments and the human 34 microbiome, this approach is nowadays changing how physicians diagnose infectious diseases². 35 Whereas amplicon based metagenomics has been successfully adopted for bacterial diagnostics, no 36 amplicon based pan-viral approach is available and therefore viral metagenomics has not yet been 37 widely deployed as diagnostic tool in clinical laboratories¹. One of the main challenges for application 38 in clinical settings is the low level of viral genomes in the presence of high levels of host material in 39 patient samples. Several methods for depletion of host sequences and enrichment of viral sequences 40 have been studied with varying success rates 11 . For example, depletion of host cells prior to extraction 41 of nucleic acids (NA) has been reported to be not advantageous in clinical samples as also intracellular 42 viral particles or NA will be removed^{11,12}. In contrast, viral enrichment by probe hybridization methods 43 has been reported to significantly increase sensitivity in various sample types^{1,13-19}, up to the level 44 required for accurate detection of low frequency virus variants²⁰.

45 Previously, the performance of a hybridization capture probe panel targeting vertebrate viruses in 46 cerebrospinal fluids from patients with meningo-encephalitis has been analysed²¹. Viral target 47 sequence read counts increased 100-10.000 fold compared to unenriched metagenomic sequencing, 48 and sensitivity by enrichment was comparable with polymerase chain reaction (PCR)²¹. Moreover, 49 these earlier data showed that this hybridisation panel of approximately two million capture probes 50 designed in 2015 was suited for the detection of novel coronaviruses by reactivity with other 51 vertebrate betacoronavirus probes¹⁰. During the past years, this specific hybridisation panel 52 distributed by Roche has been adopted in a broad range of different clinical^{15,22-29} and zoonotic 53 settings^{22,29,30}. Recently, Twist Bioscience has released a new hybridisation panel containing 54 approximately one million size capture probes targeting human and animal viruses. Reports 55 comparing the performance of viral metagenomic hybridisation panels are lacking.

 Here, we compare the analytical performance of two targeted metagenomic virus capture probe- based methods: i) SeqCap EZ HyperCap by Roche (ViroCap) and ii) Twist Comprehensive Viral Research Panel workflow, for clinical diagnostic use. Sensitivity, specificity, and limit of detection were analysed using synthetic viral sequences, clinical and reference samples with known viral loads.

Methods

- Synthetic sequences and clinical samples
- An overview of the validation panels and study design is shown in **Figure 1**.

 In order to mimic the complexity of clinical samples while reducing the number of additional viral sequences, enabling sensitivity and specificity analyses, a panel was prepared of synthetic viral 66 sequences (10⁰ - 10⁷ copies/ml) spiked in human cell free DNA (cf DNA) background sequences (Twist Bioscience, San Francisco, USA). Synthetic viral sequences covered >99.9% of the viral genomes of SARS-CoV-2, influenza A virus (Inf A), measles, enterovirus D68, and bocavirus and were mixed with several proportions of human cfDNA (90-99.999% of weight, corresponding with proportions of up to $10-0.001\%$ ³¹ of viral nucleotides in a clinical sample^{12,32,33}). Concentrations of viral sequences were 71 determined by digital droplet PCR in triplicate (BioRad QX200). A total of 25 of synthetic mixtures were included (see **Suppl. Table 1**).

 Clinical EDTA plasma samples (n=8), previously submitted to the Clinical Microbiological Laboratory 74 for routine diagnostic testing and tested positive by $qPCR^{21,34}$ for adenovirus (ADV), Epstein-Barr virus (EBV) and Hepatitis B virus (HBV), were included in the comparison. Viral loads ranged from 500 to 50,000 International Units (IU)/ml.

 In addition, a dilution of ATCC Virome Virus Mix (MSA-2008™, ATCC, Manassas, USA) of cultivated adenovirus type F (ADV), cytomegalovirus (CMV), respiratory syncytial virus (RSV), influenza B virus, reovirus 3, and zika virus was included.

Ethical approval

 This study was approved by the medical ethics review committee Leiden/The Hague/Delft (CME number B20.002, 2020/2022).

-
- Nucleic acids extraction

 Clinical samples and the ATCC whole virus mixture were subjected to extraction of total nucleic acids (NA) using the MagNAPure 96 DNA and Viral NA Small volume extraction kit (Roche, Basel, 88 Switzerland) as described previously²¹.

Viral metagenomic next-generation sequencing (mNGS)

Twist Comprehensive Viral Research Panel workflow

 Sample preparation was performed using the Comprehensive Viral Research Panel workflow (Twist 93 Bioscience Corp.) according to the manufacturer's instructions. In short, 5 µl of NA was used as input for cDNA synthesis (Protoscript, New England Biolabs, Inc) followed by purification using magnetic beads, enzymatic fragmentation for 15 minutes at 30 °C, end repair and dA-tailing (Twist EF Library Prep 2.0, Twist Bioscience Corp.). Next, unique molecular identifier (UMI) adapters with unique dual barcodes (Twist UMI Adapter System, Twist Bioscience Corp.) were ligated to the fragments and amplified using PCR (12 cycles). Amplified libraries were pooled per 8 samples and library pools were 99 used for hybridization with the Twist Comprehensive Virus probe panel, consisting of \sim 1 million 120 bp probes targeting 15,488 different viral strains infecting human and animals. Hybridization was performed for 16 hours of incubation followed by several wash steps. Captured fragments were further amplified by a post-hybridization PCR (15 cycles). Finally, captured libraries were purified by a bead clean up using AmpureXP, and quantity and fragment size were determined using Qubit (Thermo Fisher, Waltham, MA, USA) and Fragment Analyser (Agilent, Santa Clara, CA, USA) respectively. Libraries were clustered and approximately 1 million 150bp paired-end reads were generated per sample, according to manufacturer's protocols (Illumina Inc.) at GenomeScan B.V. using the NovaSeq6000.

SeqCap EZ HyperCap (ViroCap design, Roche)

 The SeqCap EZ HyperCap workflow (Roche, Madison, USA) was performed as validated and described 111 previously^{10,21,35}. Briefly, 5 ul of NA was used as direct input (without concentration step) for enzymatic fragmentation and cDNA synthesis using the NEBNext Ultra II Directional RNA Library preparation kit V3.0 (New England Biolabs, Ipswich, MA, USA) for Illumina with several in-house adaptationsto enable 114 simultaneous detection of both DNA and RNA in a single tube per sample^{12,32}. After purification, dual barcodes (NEBNext Multiplex oligos for illumina 96 unique dual index primer pairs) were attached to the fragments and amplified using PCR (21 cycles). Four barcoded samples including controls were pooled, COT (enriched for repetitive sequences) human DNA and HyperCap Universal Blocking Oligos were added before purification, following incubation for >40 hours with the SeqCap EZ HyperCap v1 119 (ViroCap design, 2015¹⁴), a collection of approximately two million oligonucleotide probes (70–120 mers) targeting all known vertebrate viruses. A complete list of the viral taxa included can be found in 121 the supplementary tables of the manuscript by Briese et al¹⁴. Captured fragments were further

 amplified by a post-hybridization PCR (14 cycles). Finally, captured libraries were purified by bead clean up using AmpureXP, and quantity and fragment sizes were determined using Qubit (Thermo Fisher, Waltham, MA, USA) and Fragment Analyser (Agilent, Santa Clara, CA, USA), respectively. Approximately 10 million 150 bp paired-end reads were sequenced per sample according to manufacturer's protocols (Illumina Inc.) at GenomeScan B.V. using the NovaSeq6000.

127

128 Data analysis

129 Bioinformatic analysis

130 Image analysis, base calling, and quality check of sequence data were performed with the Illumina 131 data analysis pipelines RTA3.4.4 and bcl2fastq v2.20 (Illumina). Sequence data obtained using both 132 probe capture metagenomics methods were analyzed using a previously validated^{10,21,36,37} 133 bioinformatics pipeline. After quality pre-processing and removal of human reads (by mapping them 134 to the human reference genome GRCh38 135 [\(https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.26/](https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.26/) with Bowtie2³⁸ version 2.3.4), 136 datasets were analyzed using Genome Detective³⁹ version 2.48 (accessed April – May 2023) as 137 described previously³⁶. Genome Detective includes *de novo* assembly and both nucleotide and amino 138 acid based classification in combination with a RefSeq / Swiss-Prot Uniref database by Genome 139 Detective³⁹

140 Read counts were normalized for total read count and genome size using the formula: reads per 141 kilobase per million (RPKM) = (number of reads mapped to the virus genome Y $*$ 10⁶) / (total number 142 of reads $*$ length of the genome in kb)³⁷. To enable analyses of the percentage of genome coverage 143 per one million total reads, one million raw reads were randomly selected³² from the 10 million reads 144 generated for the Roche protocol. The random selection from raw FASTQ files was performed with 145 the seqtk tool [\(https://github.com/lh3/seqtk,](https://github.com/lh3/seqtk) version 1.3).

146

147 Performance metrics and statistical analyses

148 Sensitivity and specificity were calculated using the results from the synthetic viral sequences and the 149 ATCC Virome Virus mix. Additional findings were considered false positives, and non-vertebrate 150 viruses were excluded from analyses. Receiver Operating Characteristic (ROC) curves were generated 151 by varying the number of sequence-read counts used as cut-off for defining a positive result, given a 152 prerequisite of $≥3$ genome regions covered⁴⁰, and area under the curves (AUC) were calculated.

It is made available under a CC-BY-ND 4.0 International license. perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.08.23.23294459;](https://doi.org/10.1101/2023.08.23.23294459) this version posted August 24, 2023. The copyright holder for this
preprint <mark>(which was not certified by peer review)</mark> is the author/funder, who has grant

- Spearman correlations of sequence read counts with viral load, as determined by qPCR and ddPCR,
- were analyzed.
- Limits of detection for both methods were determined using 10-fold serial dilutions of synthetic viral
- NA in human cfDNA background, and undiluted clinical samples. Reproducibility was determined by
- analyzing the coefficient of variance between runs.
- Statistical analyses were performed using SPSS version 25 and 29. Statistics with P-values of 0.05 and
- lower were considered significant.

Results

Analytic sensitivity, specificity, and ROC

 Detection of synthetic viral sequences in human cfDNA background, and the Virome Virus Mix, using the Twist Comprehensive Viral Research Panel and the SeqCap EZ HyperCap (ViroCap) workflow is 165 depicted in **Suppl. Table 1**. For both methods, sensitivity was 100% (23/23, cycle threshold, C_T, values ranging from 20 to 32). Viral target read counts ranged from 334-872,042 reads per million (RPM) for the Twist Comprehensive Viral Research workflow, and 2,171- 971,610 RPM for the SeqCap EZ HyperCap workflow. Genome coverage ranged from 91.1-100% (median 99.8%), and 8.4-100% (median 97.5%), for these respective methods. Sensitivity and specificity were calculated for different thresholds for defining a positive result: i) sequence read counts and ii) genome coverage percentage, as depicted in **Figure 2** and **Table 1**. For calculation of the percentage of the viral genomes covered, a random selection of 1 million sequence reads per dataset were used. **Figure 2** shows that both RPM and genome coverage were distinctive parameters for defining a true positive result, with AUC of 99.8% for both methods when considering RPM as parameter, and ≥99.7% when considering genome coverage as parameter. Sensitivity and specificity scores of ≥95% were accomplished for both methods when 500 RPM was set as threshold, on top of a prerequisite of minimum of three distributed regions of the genome being covered (**Table 1**). Similarly, when coverage was set at 10% of the genome, both methods reached sensitivity and specificity levels of 95% and higher. Increasing the threshold for genome coverage resulted in decreased sensitivity for the SeqCap EZ HyperCap workflow, whereas it did not negatively affect the outcomes of the Twist Comprehensive Viral Research Panel workflow.

Correlation of viral load and sequence read counts

 Viral loads as determined by ddPCR on synthetic viral sequences in human cfDNA background, and by qPCR on clinical plasma samples, were compared with sequence read counts normalized by total library size and genome size (**Figure 3**). Read counts were significantly correlated with viral loads, for both methods. Outliers were detected for samples with low viral loads, likely attributable to the stochastic effect around the limits of detection of PCR and the sequencing protocols.

Limits of detection

 The limits of detection of both probe capture methods were analysed for several ssRNA, dsDNA, and ssDNA viruses, and is shown in **Figure 4** and **Suppl. Table 1**. The limits of detection for the RNA viruses

tested were approximately 50 and 500 copies/mL for the Twist Comprehensive Viral Research Panel

workflow and the SeqCap EZ HyperCap workflow, respectively. For the DNA viruses tested, the LOD

was approximately 500 IU/ml for both methods, apart from the limit of detection of HBoV, which was

approximately 5,000 c/ml using the SeqCap EZ HyperCap workflow.

Reproducibility

 Between-run variability as generated by both probe hybridization metagenomic workflows was studied by repeated testing of clinical samples and synthetic sequences in presence of human cfDNA background (**Figure 5** and **Suppl. Table 1**). Normalized sequence read counts and genome coverage percentage were analysed. Differences in target virus RPKM between runs were relatively low, ranging from 0.0 to 4.7% coefficients of variance.

Effect of human background sequences

 The qualitative and quantitative effects of increased proportion of human background sequences on the detection of viral target sequences was studied using synthetic viral sequences spiked in a varying amount of human cfDNA background sequences (90% versus 99.999%, **Suppl. Figure 1**). No qualitative negative effect was found when the human cfDNA background proportion was increased. Quantitative target virus read counts were reduced in a single sample in which non-human reads were accounted for the largest proportion of the read count. Overall, these data indicated effective capture of target sequences.

Application of determined thresholds to clinical samples

 Optimal thresholds for defining a positive result, determined as described above (using synthetic viral sequences and the Virome Virus mixture) were applied to the eight clinical plasma samples with known viral loads (**Suppl. Table 1**). All qPCR positive findings were positive by mNGS, for both methods. Additional findings when applying a threshold of minimal 500 RPM in combination with 10% coverage of at least three regions of the genome were: torque teno viruses, adeno-associated dependoparvovirus A, and polyomaviruses. The additional findings were consistent for both methods, except for Merkel cell polyomavirus which was detected using the SeqCap EZ HyperCap workflow in two samples, indicating environmental contamination. The internal control sequences used in our 222 laboratory, equine arteritis virus (EAV) and phocid herpes virus (PhHV, both with C_T -values of

It is made available under a CC-BY-ND 4.0 International license. perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.08.23.23294459;](https://doi.org/10.1101/2023.08.23.23294459) this version posted August 24, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

- 223 approximately 33) were not detected and not part of the design of the Twist method, in contrast to
- 224 the Roche method.

Discussion

 These data show analytical performances in ranges acceptable for clinical samples, for both probe hybridization targeted metagenomic approaches. A combination of RPM and percentage of genome coverage were optimal for defining a positive result, accompanied by sensitivity and specificity well over 95% for both methods. Limits of detection were within ranges applicable to clinical settings: 50- 231 500 c/ml for the Twist protocol when thresholds of 500 RPM and 10% were considered. While untargeted methods are intrinsically affected by the amount of background human DNA present in (tissue) samples⁴¹, the results of this study show effective capturing in increasing proportions of human cell free DNA without significantly affecting the read counts and the coverage of the virus genome. This study provides the first one-to-one comparison of two pan-viral metagenomic probe capture workflows.

 A recent report has studied a smaller probe panel targeting 29 human respiratory pathogenic viruses 238 in comparison to the VirCapSeq (Roche)⁴². The authors conclude that the Twist Respiratory Virus Panel workflow was suited for detection of both respiratory co-infections and SARS-CoV-2 variants with >90% tenfold genome coverage. The latter is in line with our current data: genome coverage was generally 90-100% for samples ≥1,000 C/ml, for a range of RNA and DNA viruses. It must be noted that the required pooling of samples prior to hybridization lead to lower amounts of total reads generated for lower biomass samples. Though this potentially may result in underestimation of the performance, in practice, the sensitivity was 100% despite lower total counts in some cases using the Twist workflow. Another report was recently published on the use of the Twist Comprehensive Viral Research Panel aiming at detection of viruses involved in pediatric hepatitis cases of unknown origin, 247 while an association with AAV2 was hypothesised⁴³. In 17 cases, AAV2 was detected using targeted sequencing, while in seven of these pediatric cases AAV2 was missed by untargeted metagenomic sequencing, illustrating the significance of the use of enrichment by hybridization. With regard to cost- efficiency, a recent study compared PCR, sequence-independent single primer amplification (SISPA), 251 and the Twist Comprehensive Viral Research Panel for the detection of Japanese encephalitis⁴⁴. The authors concluded that the PCR panels were not able to detect all genotypes, whereas broader 253 surveillance of vector-borne pathogens would be more effective though costly⁴⁴. Hybridization capture has been approved by the FDA for SARS-CoV-2 variant monitoring, illustrating the acknowledged significance of this type of enrichment. The limit of detection of the SARS-CoV-2 specific 256 hybridization method in their study was 800 copies/ml⁴⁵, in line with our current and previous^{10,46} 257 findings when using the broader panel. Even using the panel designed in 2015¹⁴ resulted in excellent genome coverage of SARS-CoV-2 due to sequence homology with animal coronaviruses and the 259 variability in the probe design allowing for sequence mismatches¹⁰.

 This study has several limitations. The synthetic sequences spiked in cell free human DNA did not contain other background nucleic acids such as bacterial and human RNA, though the latter proportion 262 is generally low ($5\%^{47}$ dependent on the sample type). Furthermore, though ssRNA, dsDNA, and ssDNA viruses were analyzed, detection and LOD results cannot be directly extrapolated to every single virus. These parameters may vary to some extent for different viruses, particularly those not included in the synthetic controls (manufactured by Twist). This was also exemplified by the lack of detection of EAV and PhHV using the Twist Comprehensive Viral Research panel. Though these viruses 267 are not considered human pathogens, this illustrates the presence of certain restrictions with regard to the animal viruses included in the panel. Further analyses of the lists of viruses delivered by the probe designers showed that all pathogens on the WHO list of diseases with pandemic potential [\(https://www.who.int/news/item/21-11-2022-who-to-identify-pathogens-that-could-cause-future-](https://www.who.int/news/item/21-11-2022-who-to-identify-pathogens-that-could-cause-future-outbreaks-and-pandemics)

[outbreaks-and-pandemics\)](https://www.who.int/news/item/21-11-2022-who-to-identify-pathogens-that-could-cause-future-outbreaks-and-pandemics) are present, in both probe panels.

To summarize, this study provides data supporting further steps towards widespread introduction of

viral metagenomics for pathogen detection in clinical settings. In addition, it provides guidance for

integration of probe hybridization methods in surveillance to track pathogens of pandemic potential

275 in low biomass samples such as wastewater and wild life swabs 49 .

Author's contribution

- Conceptualization: JJCV. Software: IS, Investigation; KM, AB. Methodology; KM, ECJC, JJCV. Software;
- IS. Formal analysis: KM, IS. Supervision; ECC, AB, SAB, JJCV. Visualization: KM, JJCV. Roles/Writing -

original draft; KM, JJCV. Writing - review & editing: all authors.

Declaration of potential competing interest

 DM and AB are employees of GenomeScan B.V. and provided the sequencing service. They were not involved in bioinformatic/statistical data analysis, nor interpretation of results.

Funding

 This study was partially funded by Corona accelerated R&D in Europe (CARE Innovative Medicines Initiative, IMI).

It is made available under a CC-BY-ND 4.0 International license.

- 290 **Table 1**. Sensitivity and specificity resulting from varying thresholds based on **a**, sequence read counts 291 and **b**, genome coverage percentage using a random selection of 1 million sequence reads per dataset, 292 for the capture probe based metagenomic workflows SeqCap EZ HyperCap (Roche) and Twist 293 Comprehensive Viral Research Panel workflow. Corresponding ROCs are shown in **Fig. 2**. RPM; read 294 counts per million, LOD; limit of detection. For all tables, a minimum of three distributed regions of 295 the genome covered was set as primary parameter for defining detection.
- 296 **a**

297 **b**

298 *Based on LOD of Inf A, SARS-CoV-2, EBV, HBV, and bocavirus. Inf A; influenza A virus, EBV, Epstein-

299 Barr virus, HBV, hepatitis B virus.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.08.23.23294459;](https://doi.org/10.1101/2023.08.23.23294459) this version posted August 24, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

It is made available under a CC-BY-ND 4.0 International license.

It is made available under a CC-BY-ND 4.0 International license.

 20 Lythgoe, K. A. *et al.* SARS-CoV-2 within-host diversity and transmission. *Science* **372** (2021). <https://doi.org:10.1126/science.abg0821> 21 Carbo, E. C. *et al.* Improved diagnosis of viral encephalitis in adult and pediatric hematological patients using viral metagenomics. *J Clin Virol* **130**, 104566 (2020). <https://doi.org:10.1016/j.jcv.2020.104566> 22 Schuele, L. *et al.* Assessment of Viral Targeted Sequence Capture Using Nanopore Sequencing Directly from Clinical Samples. *Viruses* **12** (2020).<https://doi.org:10.3390/v12121358> 23 Wylie, K. M. *et al.* Detection of Viruses in Clinical Samples by Use of Metagenomic Sequencing and Targeted Sequence Capture. *J Clin Microbiol* **56** (2018). <https://doi.org:10.1128/JCM.01123-18> 24 Jansen, S. A. *et al.* Broad Virus Detection and Variant Discovery in Fecal Samples of Hematopoietic Transplant Recipients Using Targeted Sequence Capture Metagenomics. *Front Microbiol* **11**, 560179 (2020).<https://doi.org:10.3389/fmicb.2020.560179> 25 Stout, M. J., Brar, A. K., Herter, B. N., Rankin, A. & Wylie, K. M. The plasma virome in longitudinal samples from pregnant patients. *Front Cell Infect Microbiol* **13**, 1061230 (2023). <https://doi.org:10.3389/fcimb.2023.1061230> 26 Garand, M. *et al.* Virome Analysis and Association of Positive Coxsackievirus B Serology during Pregnancy with Congenital Heart Disease. *Microorganisms* **11** (2023). <https://doi.org:10.3390/microorganisms11020262> 27 Flerlage, T. *et al.* Single cell transcriptomics identifies distinct profiles in pediatric acute respiratory distress syndrome. *Nat Commun* **14**, 3870 (2023). <https://doi.org:10.1038/s41467-023-39593-0> 28 Cassidy, H. *et al.* Exploring a prolonged enterovirus C104 infection in a severely ill patient using nanopore sequencing. *Virus Evol* **8**, veab109 (2022)[. https://doi.org:10.1093/ve/veab109](https://doi.org:10.1093/ve/veab109) 29 Esnault, G. *et al.* Assessment of Rapid MinION Nanopore DNA Virus Meta-Genomics Using Calves Experimentally Infected with Bovine Herpes Virus-1. *Viruses* **14** (2022). <https://doi.org:10.3390/v14091859> 30 Zhang, C. *et al.* Characterization of the Eukaryotic Virome of Mice from Different Sources. *Microorganisms* **9** (2021).<https://doi.org:10.3390/microorganisms9102064> 31 Junier, T. *et al.* Viral Metagenomics in the Clinical Realm: Lessons Learned from a Swiss-Wide Ring Trial. *Genes (Basel)* **10** (2019).<https://doi.org:10.3390/genes10090655> 32 van Boheemen, S. *et al.* Retrospective Validation of a Metagenomic Sequencing Protocol for Combined Detection of RNA and DNA Viruses Using Respiratory Samples from Pediatric Patients. *J Mol Diagn* **22**, 196-207 (2020)[. https://doi.org:10.1016/j.jmoldx.2019.10.007](https://doi.org:10.1016/j.jmoldx.2019.10.007) 33 Morfopoulou, S. *et al.* Deep sequencing reveals persistence of cell-associated mumps vaccine virus in chronic encephalitis. *Acta Neuropathol* **133**, 139-147 (2017). <https://doi.org:10.1007/s00401-016-1629-y> 34 Carbo, E. C. *et al.* Longitudinal Monitoring of DNA Viral Loads in Transplant Patients Using Quantitative Metagenomic Next-Generation Sequencing. *Pathogens* **11** (2022). <https://doi.org:10.3390/pathogens11020236> 35 Reyes, A. *et al.* Viral metagenomic sequencing in a cohort of international travellers returning with febrile illness. *J Clin Virol* **143**, 104940 (2021)[. https://doi.org:10.1016/j.jcv.2021.104940](https://doi.org:10.1016/j.jcv.2021.104940) 36 Carbo, E. C. *et al.* Performance of Five Metagenomic Classifiers for Virus Pathogen Detection Using Respiratory Samples from a Clinical Cohort. *Pathogens* **11** (2022). <https://doi.org:10.3390/pathogens11030340> 37 de Vries, J. J. C. *et al.* Benchmark of thirteen bioinformatic pipelines for metagenomic virus diagnostics using datasets from clinical samples. *J Clin Virol* **141**, 104908 (2021). <https://doi.org:10.1016/j.jcv.2021.104908> 38 Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**, 357- 359 (2012)[. https://doi.org:10.1038/nmeth.1923](https://doi.org:10.1038/nmeth.1923)

It is made available under a CC-BY-ND 4.0 International license.

- 39 Vilsker, M. *et al.* Genome Detective: an automated system for virus identification from high- throughput sequencing data. *Bioinformatics* **35**, 871-873 (2019). <https://doi.org:10.1093/bioinformatics/bty695>
- 40 de Vries, J. J. C. *et al.* Recommendations for the introduction of metagenomic next-generation sequencing in clinical virology, part II: bioinformatic analysis and reporting. *J Clin Virol* **138**, 104812 (2021).<https://doi.org:10.1016/j.jcv.2021.104812>
- 41 Lewandowska, D. W. *et al.* Optimization and validation of sample preparation for metagenomic sequencing of viruses in clinical samples. *Microbiome* **5**, 94 (2017). <https://doi.org:10.1186/s40168-017-0317-z>
- 42 Kim, K. W. *et al.* Respiratory viral co-infections among SARS-CoV-2 cases confirmed by virome capture sequencing. *Sci Rep* **11**, 3934 (2021).<https://doi.org:10.1038/s41598-021-83642-x>
- 43 Servellita, V. *et al.* Adeno-associated virus type 2 in US children with acute severe hepatitis. *Nature* **617**, 574-580 (2023).<https://doi.org:10.1038/s41586-023-05949-1>
- 44 Crispell, G. *et al.* Method comparison for Japanese encephalitis virus detection in samples collected from the Indo-Pacific region. *Front Public Health* **10**, 1051754 (2022). <https://doi.org:10.3389/fpubh.2022.1051754>
- 45 Nagy-Szakal, D. *et al.* Targeted Hybridization Capture of SARS-CoV-2 and Metagenomics Enables Genetic Variant Discovery and Nasal Microbiome Insights. *Microbiol Spectr* **9**, e0019721 (2021).<https://doi.org:10.1128/Spectrum.00197-21>
- 46 Carbo, E. C. *et al.* A comparison of five Illumina, Ion Torrent, and nanopore sequencing technology-based approaches for whole genome sequencing of SARS-CoV-2. *Eur J Clin Microbiol Infect Dis* **42**, 701-713 (2023)[. https://doi.org:10.1007/s10096-023-04590-0](https://doi.org:10.1007/s10096-023-04590-0)
- 47 Wu, J. *et al.* Ribogenomics: the science and knowledge of RNA. *Genomics Proteomics Bioinformatics* **12**, 57-63 (2014).<https://doi.org:10.1016/j.gpb.2014.04.002>
- 48 Clark, J. R. *et al.* Wastewater pandemic preparedness: Toward an end-to-end pathogen monitoring program. *Front Public Health* **11**, 1137881 (2023). <https://doi.org:10.3389/fpubh.2023.1137881>
- 49 Lwande, O. W. *et al.* Alphacoronavirus in a Daubenton's Myotis Bat (Myotis daubentonii) in Sweden. *Viruses* **14** (2022).<https://doi.org:10.3390/v14030556>

Study design and workflow

Fig. 1. Workflows of the capture probe-based targeted metagenomic protocols compared in this study, Twist Comprehensive Viral Research, and the SeqCap EZ HyperCap (ViroCap, Roche) and, both in combination with identical bioinformatic analyses pipeline. Created using BioRender.

Fig. 2. Receiver operating characteristic curves (ROC) for prediction of detection of viral sequences using the virus capture probe based metagenomic workflows Twist Comprehensive Viral Research, and SeqCap EZ HyperCap (Roche). The validation panel consisted of synthetic viral sequences spiked in a background of human cell-free DNA (90-99.999%) and diluted ATCC Virome virus mix standard (copies/mL ranging from 10⁴ to 10⁷). a, ROC based on sequence read counts per million (RPM), and **b**, percentage of genome coverage, using a random selection of 1 million sequence reads per dataset. For all curves a minimum of three distributed regions of the genome covered was set as primary parameter for defining detection.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.08.23.23294459;](https://doi.org/10.1101/2023.08.23.23294459) this version posted August 24, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

Fig. 3. **Correlation graph depicting linearity between the viral load (VL, log¹⁰ IU and C/ml, horizontally) and the log¹⁰ read counts per million per kb genome (RKPM)** as generated using the virus capture probe based metagenomic workflows Twist Comprehensive Viral Research and SeqCap EZ HyperCap (Roche). Included are detections by both methods from synthetic viral sequences spiked in a background of human cell-free DNA (90/99%), dilution series (see **Fig. 4**), and clinical samples.

Fig. 4. Limit of detection of viral sequences using the virus capture probe based metagenomic workflows Twist Comprehensive Viral Research (depicted in the left upper corner, 'C'), and SeqCap EZ HyperCap (Roche, depicted in the right lower corner, 'H'). Read counts per million per kb genome (RPKM) are shown for different viral loads (C/ml). The samples consisted of synthetic viral sequences spiked in a background of human cell-free DNA (90-99,999%) (Inf A, SARS-CoV-2, HBoV), and clinical EDTA plasma samples (ADV, EBV, HBV). Created using BioRender.

It is made available under a CC-BY-ND 4.0 International license.

Fig. 5. Reproducibility of read counts and genome coverage percentages. Between-run variability in RPKM (left axis) and genome coverage percentage (right axis) as generated using the virus capture probe based metagenomic workflows Twist Comprehensive Viral Research and SeqCap EZ HyperCap (Roche). Percentage of genome coverage was based on a random selection of 1 million sequence reads per dataset. Coefficients of variance in RPKM ranged from 0.0-4.7% (see **Suppl. Table 1**). Created using BioRender.